The 65th Annual Meeting of the American Society of Hematology (ASH) will be held in San Diego, USA, from December 9-12, 2023. As one of the world’s largest and most prestigious hematology academic conferences, the ASH Annual Meeting brings together well-known hematology experts from all over the world every year to share the most cutting-edge research progress and breakthrough clinical outcomes.

TGRX-678: Two latest research abstracts were accepted for oral presentation and poster display at the 65th ASH conference.

TGRX-678, a novel BCR-ABL allosteric inhibitor for the treatment of chronic myeloid leukemia (CML), is set to present the results of its Phase I clinical trial and preclinical research for the first time at the 2023 ASH Annual Meeting.

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster Ⅱ

TGRX-678 is a novel BCR-ABL allosteric inhibitor for Chronic Myeloid Leukemia (CML). Unlike the marketed 1st-3rd generation BCR-ABL Tyrosine Kinase Inhibitors (TKIs) that act at the catalytic site, TGRX-678 was developed by specifically targeting the ABL myristol pocket (STAMP), thus locking the kinase into an inactive state and strongly inhibiting its kinase activity. TGRX-678 has the potential to treat refractory and resistant CML patients, including those who failed Ponatinib or Asciminib. TGRX-678 is currently undergoing clinical trials both in China and in US.